Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

Crest, Colgate lawsuits target fluoride in kids' toothpaste, mouth rinse Legalcategory· January 14, 2025 U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstructive sleep apnea. OSA causes airway collapses during sleep and ...

Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

The building was temporarily converted into an overflow hospital during the COVID-19 pandemic. The CA left the building in ...